Report cover image

Global Colorectal Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 194 Pages
SKU # APRC20552947

Description

Summary

According to APO Research, The global Colorectal Cancer Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Colorectal Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Colorectal Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Colorectal Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Colorectal Cancer Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Colorectal Cancer Drugs include Sanofi, Merck & Co., Inc., Roch, Bayer, Amgen, Vaccinogen, Taiho Pharmaceutical, Sumitomo Dainippon and Regeneron, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Colorectal Cancer Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Colorectal Cancer Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Colorectal Cancer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Colorectal Cancer Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Colorectal Cancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Colorectal Cancer Drugs sales, projected growth trends, production technology, application and end-user industry.

Colorectal Cancer Drugs Segment by Company

Sanofi
Merck & Co., Inc.
Roch
Bayer
Amgen
Vaccinogen
Taiho Pharmaceutical
Sumitomo Dainippon
Regeneron
Mologen
Hutchison MediPharma
Elli Lilly
Bristol-Myers Squibb
Boehringer Ingelheim
Array BioPharma
AB Science
Colorectal Cancer Drugs Segment by Type

BRAF or MEK Inhibitors
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
Tyrosine Kinase (TKI) Inhibitors
Immunomodulators
Vascular Endothelial Growth Factor (VEGF) Inhibitors
Colorectal Cancer Drugs Segment by Application

Radiotherapy
Chemotherapy
Colorectal Cancer Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Colorectal Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Colorectal Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Colorectal Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Colorectal Cancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Colorectal Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Colorectal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Colorectal Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Colorectal Cancer Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Colorectal Cancer Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Colorectal Cancer Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Colorectal Cancer Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Colorectal Cancer Drugs Market Dynamics
2.1 Colorectal Cancer Drugs Industry Trends
2.2 Colorectal Cancer Drugs Industry Drivers
2.3 Colorectal Cancer Drugs Industry Opportunities and Challenges
2.4 Colorectal Cancer Drugs Industry Restraints
3 Colorectal Cancer Drugs Market by Manufacturers
3.1 Global Colorectal Cancer Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Colorectal Cancer Drugs Sales by Manufacturers (2020-2025)
3.3 Global Colorectal Cancer Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Colorectal Cancer Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Colorectal Cancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Colorectal Cancer Drugs Manufacturers, Product Type & Application
3.7 Global Colorectal Cancer Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Colorectal Cancer Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Colorectal Cancer Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Colorectal Cancer Drugs Tier 1, Tier 2, and Tier 3
4 Colorectal Cancer Drugs Market by Type
4.1 Colorectal Cancer Drugs Type Introduction
4.1.1 BRAF or MEK Inhibitors
4.1.2 Epidermal Growth Factor Receptor (EGFR) Inhibitors
4.1.3 Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
4.1.4 Tyrosine Kinase (TKI) Inhibitors
4.1.5 Immunomodulators
4.1.6 Vascular Endothelial Growth Factor (VEGF) Inhibitors
4.2 Global Colorectal Cancer Drugs Sales by Type
4.2.1 Global Colorectal Cancer Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Colorectal Cancer Drugs Sales by Type (2020-2031)
4.2.3 Global Colorectal Cancer Drugs Sales Market Share by Type (2020-2031)
4.3 Global Colorectal Cancer Drugs Revenue by Type
4.3.1 Global Colorectal Cancer Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Colorectal Cancer Drugs Revenue by Type (2020-2031)
4.3.3 Global Colorectal Cancer Drugs Revenue Market Share by Type (2020-2031)
5 Colorectal Cancer Drugs Market by Application
5.1 Colorectal Cancer Drugs Application Introduction
5.1.1 Radiotherapy
5.1.2 Chemotherapy
5.2 Global Colorectal Cancer Drugs Sales by Application
5.2.1 Global Colorectal Cancer Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Colorectal Cancer Drugs Sales by Application (2020-2031)
5.2.3 Global Colorectal Cancer Drugs Sales Market Share by Application (2020-2031)
5.3 Global Colorectal Cancer Drugs Revenue by Application
5.3.1 Global Colorectal Cancer Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Colorectal Cancer Drugs Revenue by Application (2020-2031)
5.3.3 Global Colorectal Cancer Drugs Revenue Market Share by Application (2020-2031)
6 Global Colorectal Cancer Drugs Sales by Region
6.1 Global Colorectal Cancer Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Colorectal Cancer Drugs Sales by Region (2020-2031)
6.2.1 Global Colorectal Cancer Drugs Sales by Region (2020-2025)
6.2.2 Global Colorectal Cancer Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Colorectal Cancer Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Colorectal Cancer Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Colorectal Cancer Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Colorectal Cancer Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Colorectal Cancer Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Colorectal Cancer Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Colorectal Cancer Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Colorectal Cancer Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Colorectal Cancer Drugs Revenue by Region
7.1 Global Colorectal Cancer Drugs Revenue by Region
7.1.1 Global Colorectal Cancer Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Colorectal Cancer Drugs Revenue by Region (2020-2025)
7.1.3 Global Colorectal Cancer Drugs Revenue by Region (2026-2031)
7.1.4 Global Colorectal Cancer Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Colorectal Cancer Drugs Revenue (2020-2031)
7.2.2 North America Colorectal Cancer Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Colorectal Cancer Drugs Revenue (2020-2031)
7.3.2 Europe Colorectal Cancer Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Colorectal Cancer Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Colorectal Cancer Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Colorectal Cancer Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Colorectal Cancer Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Sanofi Colorectal Cancer Drugs Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 Merck & Co., Inc.
8.2.1 Merck & Co., Inc. Comapny Information
8.2.2 Merck & Co., Inc. Business Overview
8.2.3 Merck & Co., Inc. Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Merck & Co., Inc. Colorectal Cancer Drugs Product Portfolio
8.2.5 Merck & Co., Inc. Recent Developments
8.3 Roch
8.3.1 Roch Comapny Information
8.3.2 Roch Business Overview
8.3.3 Roch Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Roch Colorectal Cancer Drugs Product Portfolio
8.3.5 Roch Recent Developments
8.4 Bayer
8.4.1 Bayer Comapny Information
8.4.2 Bayer Business Overview
8.4.3 Bayer Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Bayer Colorectal Cancer Drugs Product Portfolio
8.4.5 Bayer Recent Developments
8.5 Amgen
8.5.1 Amgen Comapny Information
8.5.2 Amgen Business Overview
8.5.3 Amgen Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Amgen Colorectal Cancer Drugs Product Portfolio
8.5.5 Amgen Recent Developments
8.6 Vaccinogen
8.6.1 Vaccinogen Comapny Information
8.6.2 Vaccinogen Business Overview
8.6.3 Vaccinogen Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Vaccinogen Colorectal Cancer Drugs Product Portfolio
8.6.5 Vaccinogen Recent Developments
8.7 Taiho Pharmaceutical
8.7.1 Taiho Pharmaceutical Comapny Information
8.7.2 Taiho Pharmaceutical Business Overview
8.7.3 Taiho Pharmaceutical Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Taiho Pharmaceutical Colorectal Cancer Drugs Product Portfolio
8.7.5 Taiho Pharmaceutical Recent Developments
8.8 Sumitomo Dainippon
8.8.1 Sumitomo Dainippon Comapny Information
8.8.2 Sumitomo Dainippon Business Overview
8.8.3 Sumitomo Dainippon Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Sumitomo Dainippon Colorectal Cancer Drugs Product Portfolio
8.8.5 Sumitomo Dainippon Recent Developments
8.9 Regeneron
8.9.1 Regeneron Comapny Information
8.9.2 Regeneron Business Overview
8.9.3 Regeneron Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Regeneron Colorectal Cancer Drugs Product Portfolio
8.9.5 Regeneron Recent Developments
8.10 Mologen
8.10.1 Mologen Comapny Information
8.10.2 Mologen Business Overview
8.10.3 Mologen Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Mologen Colorectal Cancer Drugs Product Portfolio
8.10.5 Mologen Recent Developments
8.11 Hutchison MediPharma
8.11.1 Hutchison MediPharma Comapny Information
8.11.2 Hutchison MediPharma Business Overview
8.11.3 Hutchison MediPharma Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Hutchison MediPharma Colorectal Cancer Drugs Product Portfolio
8.11.5 Hutchison MediPharma Recent Developments
8.12 Elli Lilly
8.12.1 Elli Lilly Comapny Information
8.12.2 Elli Lilly Business Overview
8.12.3 Elli Lilly Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Elli Lilly Colorectal Cancer Drugs Product Portfolio
8.12.5 Elli Lilly Recent Developments
8.13 Bristol-Myers Squibb
8.13.1 Bristol-Myers Squibb Comapny Information
8.13.2 Bristol-Myers Squibb Business Overview
8.13.3 Bristol-Myers Squibb Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Bristol-Myers Squibb Colorectal Cancer Drugs Product Portfolio
8.13.5 Bristol-Myers Squibb Recent Developments
8.14 Boehringer Ingelheim
8.14.1 Boehringer Ingelheim Comapny Information
8.14.2 Boehringer Ingelheim Business Overview
8.14.3 Boehringer Ingelheim Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Boehringer Ingelheim Colorectal Cancer Drugs Product Portfolio
8.14.5 Boehringer Ingelheim Recent Developments
8.15 Array BioPharma
8.15.1 Array BioPharma Comapny Information
8.15.2 Array BioPharma Business Overview
8.15.3 Array BioPharma Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Array BioPharma Colorectal Cancer Drugs Product Portfolio
8.15.5 Array BioPharma Recent Developments
8.16 AB Science
8.16.1 AB Science Comapny Information
8.16.2 AB Science Business Overview
8.16.3 AB Science Colorectal Cancer Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.16.4 AB Science Colorectal Cancer Drugs Product Portfolio
8.16.5 AB Science Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Colorectal Cancer Drugs Value Chain Analysis
9.1.1 Colorectal Cancer Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Colorectal Cancer Drugs Production Mode & Process
9.2 Colorectal Cancer Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Colorectal Cancer Drugs Distributors
9.2.3 Colorectal Cancer Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.